Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 79 entries
Sorted by: Best Match Show Resources per page
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

NPJ breast cancer

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S.
PMID: 34853355
NPJ Breast Cancer. 2021 Dec 01;7(1):150. doi: 10.1038/s41523-021-00346-1.

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients...

Cite
El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150doi: 10.1038/s41523-021-00346-1.
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S. W., Lien, H. C., Kirtani, P., Balancin, M., El Attar, H., Guleria, P., Yang, W., Shash, E., Chen, I. C., Bautista, V., Do Prado Moura, J. F., Rapoport, B. L., Castaneda, C., Spengler, E., Acosta-Haab, G., Frahm, I., Sanchez, J., Castillo, M., Bouchmaa, N., Md Zin, R. R., Shui, R., Onyuma, T., Yang, W., Husain, Z., Willard-Gallo, K., Coosemans, A., Perez, E. A., Provenzano, E., Ericsson, P. G., Richardet, E., Mehrotra, R., Sarancone, S., Ehinger, A., Rimm, D. L., Bartlett, J. M. S., Viale, G., Denkert, C., Hida, A. I., Sotiriou, C., Loibl, S., Hewitt, S. M., Badve, S., Symmans, W. F., Kim, R. S., Pruneri, G., Goel, S., Francis, P. A., Inurrigarro, G., Yamaguchi, R., Garcia-Rivello, H., Horlings, H., Afqir, S., Salgado, R., Adams, S., Kok, M., Dieci, M. V., Michiels, S., Demaria, S., Loi, S. (2021). The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ breast cancer, 7(1), 150. https://doi.org/10.1038/s41523-021-00346-1
El Bairi, Khalid, et al. "The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group." NPJ breast cancer vol. 7,1 (2021): 150. doi: https://doi.org/10.1038/s41523-021-00346-1
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 01;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355; PMCID: PMC8636568.
Copy Download .nbib Format: NLM
Protein-Ribofuranosyl Interactions Activate Orotidine 5'-Monophosphate Decarboxylase for Catalysis.

Biochemistry

Cristobal JR, Brandão TAS, Reyes AC, Richard JP.
PMID: 34726391
Biochemistry. 2021 Nov 16;60(45):3362-3373. doi: 10.1021/acs.biochem.1c00589. Epub 2021 Nov 02.

The role of a global, substrate-driven, enzyme conformational change in enabling the extraordinarily large rate acceleration for orotidine 5'-monophosphate decarboxylase (OMPDC)-catalyzed decarboxylation of orotidine 5'-monophosphate (

Cite
Cristobal JR, Brandão TAS, Reyes AC, et al. Protein-Ribofuranosyl Interactions Activate Orotidine 5'-Monophosphate Decarboxylase for Catalysis. Biochemistry. 2021;60(45):3362-3373doi: 10.1021/acs.biochem.1c00589.
Cristobal, J. R., Brandão, T. A. S., Reyes, A. C., & Richard, J. P. (2021). Protein-Ribofuranosyl Interactions Activate Orotidine 5'-Monophosphate Decarboxylase for Catalysis. Biochemistry, 60(45), 3362-3373. https://doi.org/10.1021/acs.biochem.1c00589
Cristobal, Judith R, et al. "Protein-Ribofuranosyl Interactions Activate Orotidine 5'-Monophosphate Decarboxylase for Catalysis." Biochemistry vol. 60,45 (2021): 3362-3373. doi: https://doi.org/10.1021/acs.biochem.1c00589
Cristobal JR, Brandão TAS, Reyes AC, Richard JP. Protein-Ribofuranosyl Interactions Activate Orotidine 5'-Monophosphate Decarboxylase for Catalysis. Biochemistry. 2021 Nov 16;60(45):3362-3373. doi: 10.1021/acs.biochem.1c00589. Epub 2021 Nov 02. PMID: 34726391; PMCID: PMC8650221.
Copy Download .nbib Format: NLM
Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin?.

Frontiers in physiology

Andrade DC, Haine L, Toledo C, Diaz HS, Quintanilla RA, Marcus NJ, Iturriaga R, Richalet JP, Voituron N, Del Rio R.
PMID: 30374309
Front Physiol. 2018 Oct 16;9:1440. doi: 10.3389/fphys.2018.01440. eCollection 2018.

Obstructive sleep apnea (OSA) is the most common form of sleep disordered breathing and is associated with wide array of cardiovascular morbidities. It has been proposed that during OSA, the respiratory control center (RCC) is affected by exaggerated afferent...

Cite
Andrade DC, Haine L, Toledo C, et al. Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin?. Front Physiol. 2018;9:1440doi: 10.3389/fphys.2018.01440.
Andrade, D. C., Haine, L., Toledo, C., Diaz, H. S., Quintanilla, R. A., Marcus, N. J., Iturriaga, R., Richalet, J. P., Voituron, N., & Del Rio, R. (2018). Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin?. Frontiers in physiology, 91440. https://doi.org/10.3389/fphys.2018.01440
Andrade, David C, et al. "Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin?." Frontiers in physiology vol. 9 (2018): 1440. doi: https://doi.org/10.3389/fphys.2018.01440
Andrade DC, Haine L, Toledo C, Diaz HS, Quintanilla RA, Marcus NJ, Iturriaga R, Richalet JP, Voituron N, Del Rio R. Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin?. Front Physiol. 2018 Oct 16;9:1440. doi: 10.3389/fphys.2018.01440. eCollection 2018. PMID: 30374309; PMCID: PMC6196773.
Copy Download .nbib Format: NLM
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

ESMO open

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T.
PMID: 34864501
ESMO Open. 2021 Dec 02;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 02.

No abstract available.

Cite
Reck M, Ciuleanu TE, Cobo M, et al. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open. 2021;6(6):100345doi: 10.1016/j.esmoop.2021.100345.
Reck, M., Ciuleanu, T. E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P. J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D. P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., & John, T. (2021). Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO open, 6(6), 100345. https://doi.org/10.1016/j.esmoop.2021.100345
Reck, M, et al. "Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]." ESMO open vol. 6,6 (2021): 100345. doi: https://doi.org/10.1016/j.esmoop.2021.100345
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open. 2021 Dec 02;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 02. PMID: 34864501.
Copy Download .nbib Format: NLM
The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase.

Bioorganic chemistry

Pereira MS, de Araújo SS, Nagem RAP, Richard JP, Brandão TAS.
PMID: 34965488
Bioorg Chem. 2021 Dec 16;119:105561. doi: 10.1016/j.bioorg.2021.105561. Epub 2021 Dec 16.

Salicylate hydroxylase (NahG) has a single redox site in which FAD is reduced by NADH, the O

Cite
Pereira MS, de Araújo SS, Nagem RAP, et al. The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase. Bioorg Chem. 2021;119:105561doi: 10.1016/j.bioorg.2021.105561.
Pereira, M. S., de Araújo, S. S., Nagem, R. A. P., Richard, J. P., & Brandão, T. A. S. (2021). The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase. Bioorganic chemistry, 119105561. https://doi.org/10.1016/j.bioorg.2021.105561
Pereira, Mozart S, et al. "The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase." Bioorganic chemistry vol. 119 (2021): 105561. doi: https://doi.org/10.1016/j.bioorg.2021.105561
Pereira MS, de Araújo SS, Nagem RAP, Richard JP, Brandão TAS. The role of remote flavin adenine dinucleotide pieces in the oxidative decarboxylation catalyzed by salicylate hydroxylase. Bioorg Chem. 2021 Dec 16;119:105561. doi: 10.1016/j.bioorg.2021.105561. Epub 2021 Dec 16. PMID: 34965488.
Copy Download .nbib Format: NLM
Exercising in Hypoxia and Other Stimuli: Heart Rate Variability and Ventilatory Oscillations.

Life (Basel, Switzerland)

Hermand E, Lhuissier FJ, Pichon A, Voituron N, Richalet JP.
PMID: 34203350
Life (Basel). 2021 Jun 28;11(7). doi: 10.3390/life11070625.

Periodic breathing is a respiratory phenomenon frequently observed in patients with heart failure and in normal subjects sleeping at high altitude. However, until recently, periodic breathing has not been studied in wakefulness and during exercise. This review relates the...

Cite
Hermand E, Lhuissier FJ, Pichon A, et al. Exercising in Hypoxia and Other Stimuli: Heart Rate Variability and Ventilatory Oscillations. Life (Basel). 2021;11(7)doi: 10.3390/life11070625.
Hermand, E., Lhuissier, F. J., Pichon, A., Voituron, N., & Richalet, J. P. (2021). Exercising in Hypoxia and Other Stimuli: Heart Rate Variability and Ventilatory Oscillations. Life (Basel, Switzerland), 11(7), . https://doi.org/10.3390/life11070625
Hermand, Eric, et al. "Exercising in Hypoxia and Other Stimuli: Heart Rate Variability and Ventilatory Oscillations." Life (Basel, Switzerland) vol. 11,7 (2021). doi: https://doi.org/10.3390/life11070625
Hermand E, Lhuissier FJ, Pichon A, Voituron N, Richalet JP. Exercising in Hypoxia and Other Stimuli: Heart Rate Variability and Ventilatory Oscillations. Life (Basel). 2021 Jun 28;11(7). doi: 10.3390/life11070625. PMID: 34203350; PMCID: PMC8306822.
Copy Download .nbib Format: NLM
Correction to "Origin of Free Energy Barriers of Decarboxylation and the Reverse Process of CO.

Journal of the American Chemical Society

Zhou S, Nguyen BT, Richard JP, Kluger R, Gao J.
PMID: 33822616
J Am Chem Soc. 2021 Apr 21;143(15):6018. doi: 10.1021/jacs.1c03001. Epub 2021 Apr 06.

No abstract available.

Cite
Zhou S, Nguyen BT, Richard JP, et al. Correction to "Origin of Free Energy Barriers of Decarboxylation and the Reverse Process of CO. J Am Chem Soc. 2021;143(15):6018doi: 10.1021/jacs.1c03001.
Zhou, S., Nguyen, B. T., Richard, J. P., Kluger, R., & Gao, J. (2021). Correction to "Origin of Free Energy Barriers of Decarboxylation and the Reverse Process of CO. Journal of the American Chemical Society, 143(15), 6018. https://doi.org/10.1021/jacs.1c03001
Zhou, Shaoyuan, et al. "Correction to "Origin of Free Energy Barriers of Decarboxylation and the Reverse Process of CO." Journal of the American Chemical Society vol. 143,15 (2021): 6018. doi: https://doi.org/10.1021/jacs.1c03001
Zhou S, Nguyen BT, Richard JP, Kluger R, Gao J. Correction to "Origin of Free Energy Barriers of Decarboxylation and the Reverse Process of CO. J Am Chem Soc. 2021 Apr 21;143(15):6018. doi: 10.1021/jacs.1c03001. Epub 2021 Apr 06. PMID: 33822616.
Copy Download .nbib Format: NLM
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

ESMO open

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T.
PMID: 34864501
ESMO Open. 2021 Dec 02;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 02.

No abstract available.

Cite
Reck M, Ciuleanu TE, Cobo M, et al. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open. 2021;6(6):100345doi: 10.1016/j.esmoop.2021.100345.
Reck, M., Ciuleanu, T. E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P. J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D. P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., & John, T. (2021). Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO open, 6(6), 100345. https://doi.org/10.1016/j.esmoop.2021.100345
Reck, M, et al. "Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]." ESMO open vol. 6,6 (2021): 100345. doi: https://doi.org/10.1016/j.esmoop.2021.100345
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open. 2021 Dec 02;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 02. PMID: 34864501.
Copy Download .nbib Format: NLM
Embryo quality, ploidy, and transfer outcomes in male versus female blastocysts.

Journal of assisted reproduction and genetics

Moutos CP, Kearns WG, Farmer SE, Richards JP, Saad AF, Crochet JR.
PMID: 34086149
J Assist Reprod Genet. 2021 Sep;38(9):2363-2370. doi: 10.1007/s10815-021-02250-w. Epub 2021 Jun 04.

PURPOSE: The goal is to determine if variations exist between male and female blastocysts in preimplantation measurements of quality and ploidy and in vitro fertilization elective single-embryo transfer (eSET) outcomes.METHODS: A retrospective chart review was conducted from a private...

Cite
Moutos CP, Kearns WG, Farmer SE, et al. Embryo quality, ploidy, and transfer outcomes in male versus female blastocysts. J Assist Reprod Genet. 2021;38(9):2363-2370doi: 10.1007/s10815-021-02250-w.
Moutos, C. P., Kearns, W. G., Farmer, S. E., Richards, J. P., Saad, A. F., & Crochet, J. R. (2021). Embryo quality, ploidy, and transfer outcomes in male versus female blastocysts. Journal of assisted reproduction and genetics, 38(9), 2363-2370. https://doi.org/10.1007/s10815-021-02250-w
Moutos, Christopher P, et al. "Embryo quality, ploidy, and transfer outcomes in male versus female blastocysts." Journal of assisted reproduction and genetics vol. 38,9 (2021): 2363-2370. doi: https://doi.org/10.1007/s10815-021-02250-w
Moutos CP, Kearns WG, Farmer SE, Richards JP, Saad AF, Crochet JR. Embryo quality, ploidy, and transfer outcomes in male versus female blastocysts. J Assist Reprod Genet. 2021 Sep;38(9):2363-2370. doi: 10.1007/s10815-021-02250-w. Epub 2021 Jun 04. PMID: 34086149; PMCID: PMC8490581.
Copy Download .nbib Format: NLM
Modelling the relationships between arterial oxygen saturation, exercise intensity and the level of aerobic performance in acute hypoxia.

European journal of applied physiology

Woorons X, Richalet JP.
PMID: 33782716
Eur J Appl Physiol. 2021 Jul;121(7):1993-2003. doi: 10.1007/s00421-021-04667-8. Epub 2021 Mar 30.

PURPOSE: The aim of this study was to establish a model to estimate the level of arterial oxygen saturation (SpOMETHODS: SpORESULTS: There were strong non-linear relationships between altitude and SpOCONCLUSION: The model demonstrates that the drop of SpO

Cite
Woorons X, Richalet JP. Modelling the relationships between arterial oxygen saturation, exercise intensity and the level of aerobic performance in acute hypoxia. Eur J Appl Physiol. 2021;121(7):1993-2003doi: 10.1007/s00421-021-04667-8.
Woorons, X., & Richalet, J. P. (2021). Modelling the relationships between arterial oxygen saturation, exercise intensity and the level of aerobic performance in acute hypoxia. European journal of applied physiology, 121(7), 1993-2003. https://doi.org/10.1007/s00421-021-04667-8
Woorons, Xavier, and Richalet, Jean Paul. "Modelling the relationships between arterial oxygen saturation, exercise intensity and the level of aerobic performance in acute hypoxia." European journal of applied physiology vol. 121,7 (2021): 1993-2003. doi: https://doi.org/10.1007/s00421-021-04667-8
Woorons X, Richalet JP. Modelling the relationships between arterial oxygen saturation, exercise intensity and the level of aerobic performance in acute hypoxia. Eur J Appl Physiol. 2021 Jul;121(7):1993-2003. doi: 10.1007/s00421-021-04667-8. Epub 2021 Mar 30. PMID: 33782716.
Copy Download .nbib Format: NLM
Evaluation of the Lake Louise Score for Acute Mountain Sickness and Its 2018 Version in a Cohort of 484 Trekkers at High Altitude.

High altitude medicine & biology

Richalet JP, Julia C, Lhuissier FJ.
PMID: 34515528
High Alt Med Biol. 2021 Dec;22(4):353-361. doi: 10.1089/ham.2020.0226. Epub 2021 Sep 09.

Richalet, Jean-Paul, Chantal Julia, and François J. Lhuissier. Evaluation of the Lake Louise Score for acute mountain sickness and its 2018 version in a cohort of 484 trekkers at high altitude.

Cite
Richalet JP, Julia C, Lhuissier FJ. Evaluation of the Lake Louise Score for Acute Mountain Sickness and Its 2018 Version in a Cohort of 484 Trekkers at High Altitude. High Alt Med Biol. 2021;22(4):353-361doi: 10.1089/ham.2020.0226.
Richalet, J. P., Julia, C., & Lhuissier, F. J. (2021). Evaluation of the Lake Louise Score for Acute Mountain Sickness and Its 2018 Version in a Cohort of 484 Trekkers at High Altitude. High altitude medicine & biology, 22(4), 353-361. https://doi.org/10.1089/ham.2020.0226
Richalet, Jean-Paul, et al. "Evaluation of the Lake Louise Score for Acute Mountain Sickness and Its 2018 Version in a Cohort of 484 Trekkers at High Altitude." High altitude medicine & biology vol. 22,4 (2021): 353-361. doi: https://doi.org/10.1089/ham.2020.0226
Richalet JP, Julia C, Lhuissier FJ. Evaluation of the Lake Louise Score for Acute Mountain Sickness and Its 2018 Version in a Cohort of 484 Trekkers at High Altitude. High Alt Med Biol. 2021 Dec;22(4):353-361. doi: 10.1089/ham.2020.0226. Epub 2021 Sep 09. PMID: 34515528.
Copy Download .nbib Format: NLM
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

NPJ breast cancer

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S.
PMID: 34853355
NPJ Breast Cancer. 2021 Dec 01;7(1):150. doi: 10.1038/s41523-021-00346-1.

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients...

Cite
El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150doi: 10.1038/s41523-021-00346-1.
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S. W., Lien, H. C., Kirtani, P., Balancin, M., El Attar, H., Guleria, P., Yang, W., Shash, E., Chen, I. C., Bautista, V., Do Prado Moura, J. F., Rapoport, B. L., Castaneda, C., Spengler, E., Acosta-Haab, G., Frahm, I., Sanchez, J., Castillo, M., Bouchmaa, N., Md Zin, R. R., Shui, R., Onyuma, T., Yang, W., Husain, Z., Willard-Gallo, K., Coosemans, A., Perez, E. A., Provenzano, E., Ericsson, P. G., Richardet, E., Mehrotra, R., Sarancone, S., Ehinger, A., Rimm, D. L., Bartlett, J. M. S., Viale, G., Denkert, C., Hida, A. I., Sotiriou, C., Loibl, S., Hewitt, S. M., Badve, S., Symmans, W. F., Kim, R. S., Pruneri, G., Goel, S., Francis, P. A., Inurrigarro, G., Yamaguchi, R., Garcia-Rivello, H., Horlings, H., Afqir, S., Salgado, R., Adams, S., Kok, M., Dieci, M. V., Michiels, S., Demaria, S., Loi, S. (2021). The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ breast cancer, 7(1), 150. https://doi.org/10.1038/s41523-021-00346-1
El Bairi, Khalid, et al. "The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group." NPJ breast cancer vol. 7,1 (2021): 150. doi: https://doi.org/10.1038/s41523-021-00346-1
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 01;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 79 entries